Sibrotuzumab is a humanized monoclonal antibody. It was specifically designed to target fibroblast activation protein α (FAPα). IL-13 is a cytokine secreted by T helper type 2 (Th2) cells, CD4 cells, natural killer T cells, mast cells, basophils, eosinophils, and nuclei. Diseases associated with IL13 include allergic rhinitis and asthma. The product, a recombinant anti-human FAP-mouse IL13 fusion protein known as Sibrotuzumab-mIL13, represents an innovative FAP-specific immunocytokine. Sibrotuzumab-mIL13 has demonstrated efficacy in binding to targets on myeloma cells and stimulating the immune system to combat myeloma.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-211 | Anti-Human FAP Recombinant Antibody (TAB-211) | ELISA, IP, FC, FuncS, Neut, IF, WB | IgG1 - kappa |
There are currently no Customer reviews or questions for VS-0624-FY95. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.